Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series

Lawrence Kasherman; Swati Garg; Nairi Tchrakian; Blaise Clarke; Katherine Karakasis; Raymond H Kim; Tracy L Stockley; Neesha Dhani; Amit M Oza; Stephanie Lheureux

doi:10.1016/j.gore.2021.100729

Can TP53 variant negative be high-grade serous ovarian carcinoma? A case series

Gynecol Oncol Rep. 2021 Feb 12:36:100729. doi: 10.1016/j.gore.2021.100729. eCollection 2021 May.

Authors

Affiliations

¹ Division of Medical Oncology & Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 1Z5, Canada.
² Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
³ Familial Cancer Clinic, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
⁴ Advanced Molecular Diagnostics Laboratory, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
⁵ Division of Clinical Laboratory Genetics, Laboratory Medicine Program, University Health Network, Toronto ON.

Abstract

•TP53 variant negative high-grade serous ovarian cancer is rare and can still show p53 abnormal immunohistochemistry.•Diagnostic and therapeutic considerations include pathologic, molecular and clinical domains.•Genetic reassessment through more comprehensive assays should be considered to ensure no missed rare or complex variants.•Presence of BRCA mutations can occur in TP53 variant high-grade serous ovarian cancer.

Keywords: Diagnosis; High grade serous ovarian cancer; Next generation sequencing; P53 immunohistochemistry; TP53 variant negative.

Publication types

Case Reports